EUCTR2019-003481-41-AT进行中（未招募）1 期
A Double-Blinded Randomized Controlled Study to Compare the Efficacy, Time to Onset, and Duration of Effect of Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •18 - 75 years of age, inclusive, at the time of Screening.
- •Has moderate to severe glabellar frown lines at maximum frown (severity score of 2 or 3 on GLS-I/GLS-S) as determined by in-clinic assessments by both the investigator and the subject (where: 0='none', 1='mild', 2='moderate', 3='severe').
- •Subject has a stable medical condition with no uncontrolled systemic disease.
- •Female subjects of childbearing potential must test negative for pregnancy and agree to use highly effective birth control during the course of the study.
- •Subjects who wear glasses must be able to adequately self-assess the severity of their glabellar lines (according to the GLS-S), without glasses obstructing the forehead area.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 176
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 24
排除标准
- •Previous treatment with any serotype of botulinum toxin for any indication within the 12 months prior to Screening, or any planned treatment with botulinum toxin of any serotype for any reason during the study (other than the investigational treatment).
- •Known hypersensitivity to either study medication or its excipients.
- •Any medical condition that may place the subject at increased risk due to exposure to botulinum toxin, including diagnosed myasthenia gravis, Eaton Lambert syndrome, amyotrophic lateral sclerosis, profound atrophy or weakness in the target muscles, or any other condition (at the investigator's discretion) that might interfere with neuromuscular function or contraindicate botulinum toxin therapy.
- •Facial laser or light treatment, microdermabrasion, superficial peels or retinoid therapy within the three months prior to Screening or planned during the study.
- •o Apart from the procedures specified above, previous treatment with any facial aesthetic procedure in the glabellar area (including chemical peeling, injection with biodegradable fillers, photo-rejuvenation) within 12 months prior to Screening or planned during the study.
- •Previous insertion of permanent material in the glabellar area, or planned insertion during the study.
- •Any planned or history of surgery in the glabellar area and/or canthal line area, or scars in the glabellar and/or canthal line.
- •Active skin disease/infection or irritation at the treatment area.
- •Inability to substantially lessen glabellar frown lines and or lateral canthal lines even by physically spreading them apart.
- •Use of a muscle relaxant within 2 weeks prior to Screening, or planned use during the study.
- •Marked facial asymmetry or ptosis of eyelid and/or eyebrow, or current facial palsy or neuromuscular junction disorders as judged by the investigator.
- •Pregnant, breastfeeding or planning to become pregnant during the study.
- •Use of prohibited medication including anticholinergic drugs, or drugs which could interfere with neuromuscular function, including aminoglycoside antibiotics and curare-like compounds within 2 weeks prior to Screening or planned during the study.
- •Planned surgery with general anesthetic (use of local anesthetic outside the glabellar area is permitted).
- •Participation in another clinical study within one month of Screening and throughout the study.
- •Previous participation in another botulinum toxin aesthetic study, which involved the treatment of glabellar, lines in combination with canthal lines and/or forehead lines in the previous 18 months.
- •Chronic drug or alcohol abuse (as per investigator discretion).
研究者
相似试验
已完成
2 期
A comparative study of UBLAC vs placebo to evaluate its safety and efficacy in children between 4 - 12 (Both inclusive)CTRI/2017/02/007810nique Biotech Limited154
已完成
不适用
A study to compare the effectiveness of multiple micronutrient supplement Vs iron and folic-acid supplement for anemia prophylaxis among pregnant women.CTRI/2020/11/028999Dr Anjusha Ranjith200
已完成
不适用
To compare effects of early oral plus tube feed versus only tube feed in terms of achieving feeding tolerance in preterm very low birth weight infants.CTRI/2017/10/010235Deenanath Mangeshkar Hospital and research center111
尚未招募
4 期
A0 study to assess safety and effectiveness of carbetocin vs oxytocin after delivery of baby in cesarean section to prevent excessive bleedingCTRI/2024/02/062831siddaganga medical college and research institute
已完成
不适用
To compare two drugs, dexamethasone and granisetron in their ability to prevent vomiting after surgery in womeCTRI/2017/11/010507Sri Ramachandra Medical College and Research Institute100